A message from Ionetix regarding COVID-19
As the COVID-19 pandemic continues to impact our lives, it has raised the bar for global Healthcare Providers (HCP) to respond to the patient population, while struggling to stay healthy themselves. We are refocusing our world class team of engineers, scientists, and technicians, to help design products to address the needs of HCPs and the critically ill patient population, while still allowing them to provide diagnosis and treatments during this time.
Ionetix continues to work closely with the healthcare community, routinely providing Ammonia N-13 radiopharmaceuticals for cardiac PET patients.
Ammonia N-13 now available at virtually any medical facility
Ionetix Corporation is a pioneering radiopharmaceutical end to end solutions provider for cardiac PET. We are changing the paradigm when it comes to access to one of the most accurate PET imaging agents for the detection of coronary artery disease, Ammonia N-13. Until now, this radiopharmaceutical was only available to a select group of institutions due to its very short half-life and the need for a large and expensive cyclotron on site. Ionetix can now provide virtually any hospital or private center with on demand Ammonia N-13 doses without the need to purchase a cyclotron!
Presented at the ASNC 2019 by the University of Michigan
“N13-ammonia produced by the Ionetix ION-12SC delivered high quality myocardial PET perfusion images in a safe and reliable manner with a rapid protocol.”